AAPG vs KYMR vs ABBV vs ARVN

For growth investors, ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) is the stronger pick with 341.

8% revenue growth year-over-year, versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). AbbVie Inc. (ABBV) offers the better valuation at 85. 5x trailing P/E (14. 3x forward), making it the more compelling value choice. Analysts rate ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +101. 3%, compared to -84. 0% for Arvinas, Inc. (ARVN). Over 10 years, the gap is even starker: ABBV returned +295. 5% versus ARVN's -36. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 34β versus Kymera Therapeutics, Inc. 's 1. 15β — meaning KYMR is approximately 240% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Arvinas, Inc. (ARVN) carries a lower debt/equity ratio of 2% versus 6% for ASCENTAGE PHARMA GROUP INTERNATIONAL — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) is pulling ahead at 341.

8% versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). On earnings-per-share growth, the picture is similar: ASCENTAGE PHARMA GROUP INTERNATIONAL grew EPS 89. 8% year-over-year, compared to -23. 8% for Kymera Therapeutics, Inc.. Over a 3-year CAGR, AAPG leads at 227. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AbbVie Inc.

(ABBV) is the more profitable company, earning 6. 9% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps 6. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for AAPG: 112.

0% to $46. 00.

In this comparison, ABBV (3.

2% yield) pays a dividend. AAPG, KYMR, ARVN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34), 3. 2% yield, +295. 5% 10Y return). Both have compounded well over 10 years (ABBV: +295. 5%, ARVN: -36. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AAPG is a small-cap high-growth stock; KYMR is a small-cap quality compounder stock; ABBV is a large-cap income-oriented stock; ARVN is a small-cap quality compounder stock. ABBV pays a dividend while AAPG, KYMR, ARVN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.